Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JBI-802 in myeloproliferative neoplasms and MDS/MPN with thrombocytosis
ACTRN12624000478516Phase 2Recruiting
- Sponsor
- Jubilant Therapeutics Inc.
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of JBI-802 in myeloproliferative disorder (MPD), myelodysplastic/myeloproliferative neoplasm (MDS/MPN), thrombocythemia and 4 more, sponsored by Jubilant Therapeutics Inc. Started Oct 2024; status: recruiting.
02
Drugs
JBI-802
03
Conditions
myeloproliferative disorder (MPD)myelodysplastic/myeloproliferative neoplasm (MDS/MPN)thrombocythemiapolycythemia vera (PV)primary myelofibrosis (PMF)
Beyond the preview
Go deeper on ACTRN12624000478516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000478516.